Cambridge, UK: 27 May 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge, exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes promoting and leveraging the world class excellence within our network by facilitating the right connections. Charles River, a global leader in drug discovery and development has become the latest company to join the One Nucleus Partner Programme. The programme is tailor-made to meet the needs of the Partner and One Nucleus members by enabling knowledge-sharing and engagement.
Wilbert Frieling, CSVP, Global Discovery, Charles River commented, “Our science is focused on providing clients with exactly what they need to improve and expedite the discovery and early-stage development of new therapies for the patients who need them. Working more closely with One Nucleus and its network of companies will allow us to provide the precise support companies are seeking, to translate their innovation as efficiently as possible.”
Tony Jones, CEO of One Nucleus expands further ‘We are delighted to welcome Charles River, a long-term member of the One Nucleus community, to the One Nucleus Partner Programme given their extensive track record of success in translational research. The fact they have supported over 80% of drugs approved by the FDA over the past three years illustrates the depth and scale of expertise they bring to the network. Having Charles River engaged to provide insights for members, as partners in the Virtual Innovation Centre and contributing to our events will bring great value to all concerned.’